Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted Novozymes Biopharma DK A/S
Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Related news

Vinge advises Ramirent in connection with its acquisition of JIAB

 Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
March 21, 2023

Vinge has advised Svea Bank AB in connection with the issuance of Additional Tier 1 Capital of SEK 300 million

 Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.
March 14, 2023

Vinge advises Anglo American in connection with investment in the Dannemora mine

 Vinge has, together with Norton Rose Fulbright, advised Anglo American Limited in connection with entering into a royalty agreement of USD 10 million and a binding term sheet for an offtake agreement with Dannemora Iron AB. Moreover, Vinge has assisted with thereto related due diligence. Dannemora Iron AB is a wholly owned subsidiary of Grängesberg Exploration Holding AB (publ).
March 14, 2023